GE Healthcare to Present hESC Derived Cardiomyocytes for Drug Safety Testing at Society of Toxicology Meeting 2011

Cardiomyocytes derived from human embryonic stem cells (hESC) on an industrial scale provide an advance towards more clinically predictive assays for assessing cardiotoxicity of new drugs. Data will be presented from high-content imaging and electrophysiological analysis of hESC derived cardiomyocytes illustrating a powerful complimentary and comprehensive approach to assessing cardiac drug liabilities.

March 9, 2011 1:00 – 2:00 pm

Presented by: Nick Thomas, Principal Scientist.

Visit booth 1308 for more information.